PAQR6

Across TCGA pan-cancer cohorts, PAQR6 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PAQR6 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PAQR6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PAQR6 expression acts as an unfavorable survival marker.

OV, MESO, and LIHC are the cancer types where PAQR6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.195	0.541	.015	18	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
LIHC	OS	Median	All	0.188	0.669	.041	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PAQR6–OV (DFS)

Open the OV breakdown →